Tweet
J Allergy Clin Immunol Glob
. 2025 Jun 23;4(4):100522.
doi: 10.1016/j.jacig.2025.100522. eCollection 2025 Nov. Fear, facts, and the future: An update on coronavirus disease 2019 vaccine-induced anaphylaxis and vaccine hesitancy among those living with allergy
Ayel Luis R Batac 1 2 3 4 5 , Kaitlyn A Merrill 6 , Michael A Golding 7 8 , Zoe Harbottle 7 8 , Nicole Askin 9 , Philippe Bégin 10 11 , Moshe Ben-Shoshan 12 13 14 , Erika Ladouceur 15 , Vladan Protudjer 16 , Jennifer L P Protudjer 7 8 17 18 19
Affiliations
Background: Despite the low incidence of coronavirus disease 2019 (COVID-19) vaccine-induced allergic reactions reported to date, concerns of such reactions have been reported in the literature among individuals with and without a history of allergic disease.
Objectives: Herein, we provide an update to a previous scoping review published by our group, focusing on COVID-19 vaccine hesitancy in relation to allergy and the incidence of anaphylactic reactions to COVID-19 vaccines.
Methods: The current review follows an a priori protocol drafted in accordance with Arksey and O'Malley's framework for methodological reviews. A comprehensive search was conducted on 4 scientific databases (CINAHL, PsycINFO, MEDLINE, Embase) to identify eligible studies published since our initial review. Eligible articles included those published between February 12, 2022, and November 10, 2023, and were retrieved using an established search process developed by content and methodological experts. Among the 2,099 unique citations, 45 articles (2.1%) were included.
Results: Consistent with previously reviewed literature, COVID-19 vaccine-induced anaphylaxis remains rare among both those with allergies and the general population. Despite the rarity of anaphylaxis, hesitancy persists among individuals with and without allergies.
Conclusions: To prepare for future pandemics, it is evident that more efforts are needed to address concerns regarding the potential for allergic reactions following vaccination. As part of this process, it is important to ensure medical professionals are updated as new information becomes available and that evidence-based risk communication is accurate, accessible, and culturally appropriate.
Keywords: Allergy; COVID-19; anaphylaxis; scoping review; vaccine hesitancy.
. 2025 Jun 23;4(4):100522.
doi: 10.1016/j.jacig.2025.100522. eCollection 2025 Nov. Fear, facts, and the future: An update on coronavirus disease 2019 vaccine-induced anaphylaxis and vaccine hesitancy among those living with allergy
Ayel Luis R Batac 1 2 3 4 5 , Kaitlyn A Merrill 6 , Michael A Golding 7 8 , Zoe Harbottle 7 8 , Nicole Askin 9 , Philippe Bégin 10 11 , Moshe Ben-Shoshan 12 13 14 , Erika Ladouceur 15 , Vladan Protudjer 16 , Jennifer L P Protudjer 7 8 17 18 19
Affiliations
- PMID: 40740414
- PMCID: PMC12309611
- DOI: 10.1016/j.jacig.2025.100522
Background: Despite the low incidence of coronavirus disease 2019 (COVID-19) vaccine-induced allergic reactions reported to date, concerns of such reactions have been reported in the literature among individuals with and without a history of allergic disease.
Objectives: Herein, we provide an update to a previous scoping review published by our group, focusing on COVID-19 vaccine hesitancy in relation to allergy and the incidence of anaphylactic reactions to COVID-19 vaccines.
Methods: The current review follows an a priori protocol drafted in accordance with Arksey and O'Malley's framework for methodological reviews. A comprehensive search was conducted on 4 scientific databases (CINAHL, PsycINFO, MEDLINE, Embase) to identify eligible studies published since our initial review. Eligible articles included those published between February 12, 2022, and November 10, 2023, and were retrieved using an established search process developed by content and methodological experts. Among the 2,099 unique citations, 45 articles (2.1%) were included.
Results: Consistent with previously reviewed literature, COVID-19 vaccine-induced anaphylaxis remains rare among both those with allergies and the general population. Despite the rarity of anaphylaxis, hesitancy persists among individuals with and without allergies.
Conclusions: To prepare for future pandemics, it is evident that more efforts are needed to address concerns regarding the potential for allergic reactions following vaccination. As part of this process, it is important to ensure medical professionals are updated as new information becomes available and that evidence-based risk communication is accurate, accessible, and culturally appropriate.
Keywords: Allergy; COVID-19; anaphylaxis; scoping review; vaccine hesitancy.